Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
CompanyDeals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Eisai's Urece (Dotinurad) Approved by China's NMPA for Gout Treatment with Hyperuricemia
CompanyDrug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation
CompanyDrug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Shanghai Pharmaceutical and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access
CompanyDeals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

China Medical System's Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use
CompanyDrug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting
CompanyDrug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

AbbVie's Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson's Disease
CompanyDrug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment
CompanyDrug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency
Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange
CompanyDeals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
CompanyDrug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Antengene's Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
CompanyDrug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024